Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141765
Recruitment Status : Completed
First Posted : September 1, 2005
Results First Posted : June 20, 2014
Last Update Posted : June 20, 2014
Information provided by (Responsible Party):
John Levine, MD, University of Michigan Cancer Center

August 31, 2005
September 1, 2005
May 19, 2014
June 20, 2014
June 20, 2014
January 1997
December 2008   (Final data collection date for primary outcome measure)
Percent of Participants With Progression Free Survival at 1 Year [ Time Frame: 1 year post transplant ]
The primary outcome measure for this study was to improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse.
To improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse.
Complete list of historical versions of study NCT00141765 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
This is a phase II trial designed to provide a transplant option for patients with rare poor-prognosis cancers. The protocol is only open to patients with metastatic or relapsed cancers for whom the probability of remaining free of progressive disease for one year after being brought into remission is < 25%. Patients eligible for this study have been diagnosed with a form of cancer that leads to death more than 75% of the time when treated with standard therapy doses of chemotherapy and/ or radiation therapy. Under this treatment intensification protocol the expectation is that the one year progression-free survival for this group of patients will rise to 40%. Patients eligible for this protocol will be followed for one year post-transplant. Patients alive and free of progressive disease at the end of this period will be considered successes.
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Wilms Tumor
  • Fibrosarcoma
  • Carcinoma, Round Cell
  • Nasopharyngeal Cancer
  • Brain Tumor, Recurrent
  • Procedure: Myeloablative Chemotherapy
    High dose chemotherapy (carboplatin and thiotepa) transplant rescue
  • Procedure: Stem Cell Rescue
    autologous stem cell transplantation
Experimental: Myeloablative Chemotherapy with Stem Cell Rescue
Myeloablative Chemotherapy, followed by stem cell rescue
  • Procedure: Myeloablative Chemotherapy
  • Procedure: Stem Cell Rescue
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2010
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be ineligible for other IRB-approved myeloablative regimens, be 21 years old or younger, and must have a histologically-confirmed Wilms' tumor, liver cancer, recurrent brain tumor of childhood, nasopharyngeal carcinoma, fibrosarcoma, desmoplastic small round cell tumor, germ cell tumor or other small round cell tumor, which:

    1. is metastatic and has < 25% cure rate with conventional treatment; or
    2. progressed after prior chemotherapy and has < 25% salvage rate with non-myeloablative therapies.
  • Disease status: Within 3 weeks of initiation of this protocol, patients must:

    1. be in a complete or good partial remission (section 7.4); or
    2. have a "chemosensitive" tumor, which is defined as a > 50% decrease in at least one measurable tumor parameter attributable to prior chemotherapy, without evidence of progressive disease by any other parameter.
  • Prior chemotherapy: Before entry to this protocol, patients must have derived maximal benefit from conventional, i.e., nonmyeloablative, doses of combination chemotherapy. Conventional therapy should be continued until either a complete remission is achieved, no further benefit from non-myeloablative dosing can be appreciated, or toxicity from conventional therapy is perceived as limiting in the absence of stem cell rescue. The cancer must be proven to be sensitive to alkylating agents. This means that, in addition to, or as part of, the appropriate chemotherapy protocol for the specific cancer in question, all patients must have received and responded to a minimum of:

    1. 2 courses of high-dose cyclophosphamide, totaling > 4200 mg/m2; or
    2. courses of high-dose ifosfamide totaling > 12 gm/m2.
    3. 1 course of "a)" above, plus 1 course of 'b)" above.
    4. Equivalent high dose alkylating agents as described in 3.3 a, b, and c.
  • Patients must have adequate renal hepatic, and cardiac function (sections 4.4-4.6).
  • Patients must meet at least one of the following stem cell requirements (Peripheral blood collection is to be preferred when available as an option):

    1. Harvested bone marrow must contain 1 x 108 nucleated cells per kg of body weight, or,
    2. Peripheral blood collection should include at least 2 x 106 CD34+ cells/kg.
  • Informed consent must be signed indicating patient and/or parental awareness of the investigational nature of this program
Sexes Eligible for Study: All
up to 21 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
UMCC 9626
IRB 1996-195
Not Provided
Not Provided
John Levine, MD, University of Michigan Cancer Center
University of Michigan Cancer Center
Not Provided
Principal Investigator: John E. Levine, MS MD The Univeristy of Michigan
University of Michigan Cancer Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP